Orgenesis Inc. ROE

ROE of ORGS for past 10 years: annual, quarterly and twelve month trailing (TTM) including ROE growth rates and interactive chart. ROE is expressed as a percentage and can be calculated for any company if net income and equity are both positive numbers. Net income is calculated before dividends paid to common shareholders and after dividends to preferred shareholders and interest to lenders. A company with average equity of $10 million and earnings of $2 milion will have a ROE of 20%.


Highlights and Quick Summary

  • Annual ROE for 2020 was -330.05% (a 131.44% increase from previous year)
  • Annual ROE for 2019 was -142.61% (a 111.96% increase from previous year)
  • Annual ROE for 2018 was -67.28% (a -21.34% decrease from previous year)
  • Twelve month ROE ending September 29, 2021 was -99.35% (a 8.71% increase compared to previous quarter)
  • Twelve month trailing ROE increased by 155.4% year-over-year
Trailing ROE for the last four month:
29 Sep '21 29 Jun '21 30 Mar '21 30 Dec '20
-99.35% -91.39% -113.18% -38.9%
Visit stockrow.com/ORGS for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical ROE of Orgenesis Inc.

Most recent ROEof ORGS including historical data for past 10 years.

Interactive Chart of ROE of Orgenesis Inc.

Orgenesis Inc. ROE for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 -330.05%
2019 -142.61%
2018 -67.28%
2017 -87.57%
2016 -88.93%
2015 94.72%
2014 219.57%
2013 478.55%
2012 0.0%
2011 0.0%

Business Profile of Orgenesis Inc.

Sector: Healthcare
Industry: Biotechnology
Orgenesis Inc., a biotech company, focusing on cell and gene therapies (CGTs). The company develops a Point of Care (POCare) platform includes three enabling components: a pipeline of licensed POCare Therapeutics that are processed and produced in closed, automated POCare Technology systems across a collaborative POCare Network. It focuses on autologous therapies, with processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated for compliant production near the patient at their point of care for treatment of the patient. The company's POCare Network brings together patients, doctors, industry partners, research institutes, and hospitals for the clinical development and production of therapies worldwide. Orgenesis Inc. has a collaboration agreement with Savicell Diagnostics Ltd. The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was incorporated in 2008 and is based in Germantown, Maryland.